Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35108470

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2022 Feb 3
First author
Doki Y

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2022 Apr;19(4):219. doi: 10.1038/s41571-022-00608-2.
    note
    Source null
    related pmid
    35169266
    relationship
    Comment in
  2. citation
    N Engl J Med. 2022 May 19;386(20):1958-1959. doi: 10.1056/NEJMc2202880.
    note
    Source null
    related pmid
    35584166
    relationship
    Comment in
  3. citation
    N Engl J Med. 2022 May 19;386(20):1959. doi: 10.1056/NEJMc2202880.
    note
    Source null
    related pmid
    35584167
    relationship
    Comment in
  4. citation
    N Engl J Med. 2022 May 19;386(20):1959-1961. doi: 10.1056/NEJMc2202880.
    note
    Source null
    related pmid
    35584168
    relationship
    Comment in
  5. citation
    Signal Transduct Target Ther. 2022 May 25;7(1):169. doi: 10.1038/s41392-022-01022-x.
    note
    Source null
    related pmid
    35614047
    relationship
    Comment in
  6. citation
    Gastroenterology. 2022 Aug;163(2):527. doi: 10.1053/j.gastro.2022.05.042.
    note
    Source null
    related pmid
    35660032
    relationship
    Comment in

Authors and identifiers

  1. name
    Doki Y
    type
    Author
  2. name
    Ajani JA
    type
    Author
  3. name
    Kato K
    type
    Author
  4. name
    Xu J
    type
    Author
  5. name
    Wyrwicz L
    type
    Author
  6. name
    Motoyama S
    type
    Author
  7. name
    Ogata T
    type
    Author
  8. name
    Kawakami H
    type
    Author
  9. name
    Hsu CH
    type
    Author
  10. name
    Adenis A
    type
    Author
  11. name
    El Hajbi F
    type
    Author
  12. name
    Di Bartolomeo M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Doki Y
    type
    Author
  2. name
    Ajani JA
    type
    Author
  3. name
    Kato K
    type
    Author
  4. name
    Xu J
    type
    Author
  5. name
    Wyrwicz L
    type
    Author
  6. name
    Motoyama S
    type
    Author
  7. name
    Ogata T
    type
    Author
  8. name
    Kawakami H
    type
    Author
  9. name
    Hsu CH
    type
    Author
  10. name
    Adenis A
    type
    Author
  11. name
    El Hajbi F
    type
    Author
  12. name
    Di Bartolomeo M
    type
    Author
bibliography ids
  1. nci-bib-2355da2f8dcc4873ee5ff88b
book metadata
content sha256
c61279a3d8fd3b7487c2ec3de18a8721e9f58b42441f20220c0107006afb6a56
document type
citation
dois
  1. 10.1056/NEJMoa2111380
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:35108470
immutable id
pubmed:35108470@c61279a3d8fd3b7487c2ec3de18a8721e9f58b42441f20220c0107006afb6a56
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
5
name
The New England journal of medicine
nlm unique id
0255562
pages
449-462
volume
386
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Clin Oncol. 2022 Apr;19(4):219. doi: 10.1038/s41571-022-00608-2.
    note
    Source null
    related pmid
    35169266
    relationship
    Comment in
  2. citation
    N Engl J Med. 2022 May 19;386(20):1958-1959. doi: 10.1056/NEJMc2202880.
    note
    Source null
    related pmid
    35584166
    relationship
    Comment in
  3. citation
    N Engl J Med. 2022 May 19;386(20):1959. doi: 10.1056/NEJMc2202880.
    note
    Source null
    related pmid
    35584167
    relationship
    Comment in
  4. citation
    N Engl J Med. 2022 May 19;386(20):1959-1961. doi: 10.1056/NEJMc2202880.
    note
    Source null
    related pmid
    35584168
    relationship
    Comment in
  5. citation
    Signal Transduct Target Ther. 2022 May 25;7(1):169. doi: 10.1038/s41392-022-01022-x.
    note
    Source null
    related pmid
    35614047
    relationship
    Comment in
  6. citation
    Gastroenterology. 2022 Aug;163(2):527. doi: 10.1053/j.gastro.2022.05.042.
    note
    Source null
    related pmid
    35660032
    relationship
    Comment in
outcomes validated
false
pmid
35108470
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
236f485cddf61ef538019b904a7af4106301dbb0027dc783c74c268169ba25b3
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Feb 3
precision
day
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35108470/
title
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

Preserved source evidence · Not medical advice